Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 2.29
INSM's Cash-to-Debt is ranked lower than
67% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. INSM: 2.29 )
Ranked among companies with meaningful Cash-to-Debt only.
INSM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.86  Med: 17.04 Max: No Debt
Current: 2.29
Piotroski F-Score: 2
Altman Z-Score: 0.24
Beneish M-Score: -4.31
WACC vs ROIC
13.05%
-344.31%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE % -87.71
INSM's ROE % is ranked lower than
72% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. INSM: -87.71 )
Ranked among companies with meaningful ROE % only.
INSM' s ROE % Range Over the Past 10 Years
Min: -361.62  Med: -44.96 Max: 195.47
Current: -87.71
-361.62
195.47
ROA % -67.09
INSM's ROA % is ranked lower than
72% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. INSM: -67.09 )
Ranked among companies with meaningful ROA % only.
INSM' s ROA % Range Over the Past 10 Years
Min: -129.17  Med: -37.18 Max: 180.06
Current: -67.09
-129.17
180.06
ROC (Joel Greenblatt) % -1800.51
INSM's ROC (Joel Greenblatt) % is ranked lower than
70% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. INSM: -1800.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INSM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -720550  Med: -2254.29 Max: -1133.76
Current: -1800.51
-720550
-1133.76
3-Year Revenue Growth Rate -100.00
INSM's 3-Year Revenue Growth Rate is ranked lower than
94% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. INSM: -100.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INSM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -14.3 Max: 481.9
Current: -100
0
481.9
3-Year EBITDA Growth Rate 21.10
INSM's 3-Year EBITDA Growth Rate is ranked higher than
74% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. INSM: 21.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
INSM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -59.4  Med: -15.9 Max: 49.2
Current: 21.1
-59.4
49.2
3-Year EPS without NRI Growth Rate 21.20
INSM's 3-Year EPS without NRI Growth Rate is ranked higher than
75% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. INSM: 21.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
INSM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -59.5  Med: -14.6 Max: 48.4
Current: 21.2
-59.5
48.4
GuruFocus has detected 3 Warning Signs with Insmed Inc $INSM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INSM's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

INSM Guru Trades in Q2 2016

Steven Cohen 201,354 sh (New)
Paul Tudor Jones 28,163 sh (+30.67%)
John Paulson 205,200 sh (unchged)
Jim Simons 149,300 sh (-18.76%)
» More
Q3 2016

INSM Guru Trades in Q3 2016

Jim Simons 197,700 sh (+32.42%)
John Paulson 205,200 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones 23,036 sh (-18.20%)
» More
Q4 2016

INSM Guru Trades in Q4 2016

John Paulson 205,200 sh (unchged)
Paul Tudor Jones 22,887 sh (-0.65%)
Jim Simons 120,500 sh (-39.05%)
» More
Q1 2017

INSM Guru Trades in Q1 2017

Steven Cohen 50,000 sh (New)
Jim Simons Sold Out
Paul Tudor Jones 15,667 sh (-31.55%)
John Paulson 90,000 sh (-56.14%)
» More
» Details

Insider Trades

Latest Guru Trades with INSM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:GNFTF, NAS:EPZM, NAS:XNCR, NAS:FOLD, OTCPK:PFSCF, OTCPK:PHMMF, NAS:XLRN, NAS:CHRS, NAS:DERM, NAS:AIMT, NAS:FWP, NAS:ZIOP, NAS:LOXO, NYSE:EBS, NAS:INSY, NAS:AKAO, NAS:ASND, NAS:ALDR, OTCPK:BPMUF, NAS:AMRN » details
Traded in other countries:IM8N.Germany,
Headquarter Location:USA
Insmed Inc is a global biotechnology company. It is focused on developing novel therapies that focus primarily on lung diseases.

Insmed Inc is a global biotechnology company that is focused on developing novel therapies for rare diseases. The company works to develop and commercialize therapies that focus primarily on lung diseases. Insmed is focused broadly on rare disease therapeutics and prioritizing its current therapeutic focus in the fields of pulmonology and infectious disease. The company's strategy includes licensing its patents and pending patent applications. The company's primary businesses are within the U.S., Europe, and Canada, while also maintaining operations in other international markets as well.

Ratios

vs
industry
vs
history
PB Ratio 8.90
INSM's PB Ratio is ranked lower than
75% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. INSM: 8.90 )
Ranked among companies with meaningful PB Ratio only.
INSM' s PB Ratio Range Over the Past 10 Years
Min: 0.45  Med: 3.78 Max: 105
Current: 8.9
0.45
105
EV-to-EBIT -5.80
INSM's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. INSM: -5.80 )
Ranked among companies with meaningful EV-to-EBIT only.
INSM' s EV-to-EBIT Range Over the Past 10 Years
Min: -34.1  Med: -4 Max: 163.9
Current: -5.8
-34.1
163.9
EV-to-EBITDA -5.88
INSM's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. INSM: -5.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
INSM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -66.8  Med: -4.3 Max: 317.3
Current: -5.88
-66.8
317.3
Current Ratio 5.66
INSM's Current Ratio is ranked higher than
62% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. INSM: 5.66 )
Ranked among companies with meaningful Current Ratio only.
INSM' s Current Ratio Range Over the Past 10 Years
Min: 0.53  Med: 7.29 Max: 54.49
Current: 5.66
0.53
54.49
Quick Ratio 5.66
INSM's Quick Ratio is ranked higher than
64% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. INSM: 5.66 )
Ranked among companies with meaningful Quick Ratio only.
INSM' s Quick Ratio Range Over the Past 10 Years
Min: 0.53  Med: 7.29 Max: 54.49
Current: 5.66
0.53
54.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.60
INSM's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. INSM: -16.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INSM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -119  Med: -26.1 Max: -5.4
Current: -16.6
-119
-5.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 22.99
INSM's Price-to-Net-Cash is ranked lower than
74% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. INSM: 22.99 )
Ranked among companies with meaningful Price-to-Net-Cash only.
INSM' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.57  Med: 4.4 Max: 197.5
Current: 22.99
0.57
197.5
Price-to-Net-Current-Asset-Value 20.28
INSM's Price-to-Net-Current-Asset-Value is ranked lower than
75% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. INSM: 20.28 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
INSM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.52  Med: 4.36 Max: 156.67
Current: 20.28
0.52
156.67
Price-to-Tangible-Book 16.90
INSM's Price-to-Tangible-Book is ranked lower than
82% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. INSM: 16.90 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
INSM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.51  Med: 4.22 Max: 85
Current: 16.9
0.51
85
Earnings Yield (Greenblatt) % -17.33
INSM's Earnings Yield (Greenblatt) % is ranked lower than
73% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. INSM: -17.33 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INSM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -17.68  Med: 25.9 Max: 15132.8
Current: -17.33
-17.68
15132.8

More Statistics

EPS (TTM) $ -2.91
Beta1.83
Short Percentage of Float9.56%
52-Week Range $9.02 - 19.35
Shares Outstanding (Mil)62.09

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 86 191
EPS ($) -2.45 -1.06 0.23
EPS without NRI ($) -2.45 -1.06 0.23
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for INSM

Headlines

Articles On GuruFocus.com
Insmed Announces Key Additions to its Executive Management Team May 15 2017 
Insmed to Present at the Deutsche Bank 42nd Annual Health Care Conference Apr 27 2017 
Insmed to Host First Quarter 2017 Financial Results Conference Call on Wednesday, May 3, 2017 Apr 26 2017 
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
Weekly CEO Buys Highlight: TPGI, INSM, EQU, FCEL Jan 13 2013 
INSMED Inc -- A Merger Ruined its Net-Net Status Feb 02 2011 
Insmed Inc. Reports Operating Results (10-Q) Nov 03 2010 
Insmed Inc. Reports Operating Results (10-Q) Aug 04 2010 
Insmed Inc. Reports Operating Results (10-Q) May 06 2010 
Jim Simons Low P/E Stocks: Insmed Inc., Paragon Shipping Inc., The Student Loan Corp., Hellenic Tele Apr 28 2010 

More From Other Websites
Edited Transcript of INSM earnings conference call or presentation 3-May-17 12:30pm GMT May 18 2017
Insmed Announces Key Additions to its Executive Management Team May 15 2017
Insmed reports 1Q loss May 03 2017
Insmed Reports First Quarter 2017 Financial Results and Provides Business Update May 03 2017
Investor Network: Insmed Incorporated to Host Earnings Call May 03 2017
Implied Volatility Surging for Insmed (INSM) Stock Options Apr 28 2017
Insmed to Present at the Deutsche Bank 42nd Annual Health Care Conference Apr 27 2017
Insmed to Host First Quarter 2017 Financial Results Conference Call on Wednesday, May 3, 2017 Apr 26 2017
Do Options Traders Know Something About Insmed Incorporated (INSM) Stock We Don't? Mar 21 2017
Insmed to Present at the Cowen and Company 37th Annual Health Care Conference Feb 28 2017
Edited Transcript of INSM earnings conference call or presentation 23-Feb-17 1:30pm GMT Feb 23 2017
Insmed Reports Fourth Quarter 2016 Financial Results and Provides Business Update Feb 23 2017
Lifshitz & Miller Law Firm Announces Investigation of Calamos Asset Management, Inc., CDI Corp.,... Jan 17 2017
Hedge Funds Sour Slightly On Insmed Incorporated (INSM), But Remain Overweight Dec 05 2016
Insmed, Inc. :INSM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 Nov 28 2016
Edited Transcript of INSM earnings conference call or presentation 3-Nov-16 12:30pm GMT Nov 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat